Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Sweden and internationally.
The last earnings update was 40 days ago.
Discounted Cash Flow Calculation for DB:2B4 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
Note: Free cash flow to equity valuations ignore the company's cash or debt.
DB:2B4 DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Bonesupport Holding's share price is below the future cash flow value, and at a moderate discount (> 20%).
Bonesupport Holding's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Bonesupport Holding's earnings available for a low price, and how does
this compare to other companies in the same industry?
Bonesupport Holding's earnings are expected to grow significantly at over 20% yearly.
Bonesupport Holding's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Bonesupport Holding's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Bonesupport Holding's finances.
The net worth of a company is the difference between its assets and liabilities.
Bonesupport Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Bonesupport Holding's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Bonesupport Holding's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is not covered by short term assets, assets are -9.7456207086435E+16x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Emil Billbäck has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executive Officer of BONESUPPORT AB. He has over 20 years management experience from the life science industry. Mr. Billbäck serves as Senior Advisor of Essity, following its acquisition of BSN Medical from the Swedish private equity group EQT in 2017. Prior to this, he was a member of the Group Executive Board/Management Committee at BSN Medical, where he held the position of Executive Vice President EMEA and Head of Global Commercial Operations. Mr. Billbäck spent over 13 years in senior management roles at BSN Medical, including Interim President of North America and Group Director Commercial Operations and R&D
Insufficient data for Emil to compare compensation growth.
Emil's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Bonesupport Holding management team is about average.
Chief Executive Officer
Founder & Director
Chief Financial Officer
COO and Executive VP of Manufacturing & Supply
Executive Vice President Global Marketing & Communications
Head of Human Resources
Executive VP of R&D
Executive Vice President of R&D
GM & Executive VP Commercial Operations EUROW
Executive Vice President of Quality Management & Regulatory Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Bonesupport Holding board of directors is about average.
Board of Directors
Chairman of the board
Founder & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Sweden and internationally. The company offers CERAMENT Bone Void Filler used to fill gaps and voids in bone; CERAMENT G, a gentamicin-eluting injectable synthetic bone substitute; and CERAMENT V, a vancomycin-eluting synthetic bone substitute. Its products are used in orthopedic markets. The company was founded in 1999 and is headquartered in Lund, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.